SLShengde Liu

Shengde Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shengde Liu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Lin Shen

    Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China

    15 shared publications
  • Zizhen Zhang

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China

    15 shared publications
  • Jian Li

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China

    14 shared publications
  • Cheng Liu

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China

    13 shared publications
  • Cheng Zhang

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China

    13 shared publications
  • Dali Han

    China National Center for Bioinformation, Beijing Institute of Genomics, Chinese Academy of Sciences 3 Department of Computational Biology, Key Laboratory of RNA Science and Engineering Beijing

    13 shared publications

Latest Publications

  • Open Access

    Figure S1 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

    Figure S1 Verification of high-metastasis mouse model and the relationship between SPP1 and clinical features. A-F Results of bright field imaging, migration, and invasion assays for LoVo, LoVo-HM, HCT116 and HCT116-HM cells are presented, n = 3 biologically independent experiments. Scale bar, 50 μm. G-J Representative metastatic livers gross morphology from NOD/SCID mice intrasplenically implanted with LoVo, LoVo-HM, HCT116 or HCT116-HM cells (n = 5 per group). K Western blot analysis of SPP1 protein levels in LoVo, LoVo-HM, HCT116, and HCT116-HM cells, n = 3 biologically independent experiments. L Expression of SPP1 gene in different cancer and normal tissues of TIMER2.0 database. M, N Association of SPP1 expression with OS (M) and DFS (N) in CRC based on TCGA data. O-Q Correlation of SPP1 expression with pathological stage, N stage and T stage in CRC patients. All results are presented as mean ± SEM. The data in M, N were determined by Kaplan–Meier analysis with the log-rank test. P values were determined by two-tailed unpaired Student’s t test (C-F, H, J, P) and one-way ANOVA (O, Q). **P < 0.01, ***P < 0.001.

  • Open Access

    Figure S6 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

    Figure S6 Talabostat mesylate reverses the progression of CRLM and synergizes with PD-1 blockade therapy A-C Collagen content assessed by Masson’s trichrome staining, and expression levels of α-SMA and CD8 evaluated by mIHC analysis. D, E Ki-67 and TUNEL staining were performed on PDOX tumor tissues to evaluate cell apoptosis and proliferation. F H&E analysis in tumor tissues from each group. G Flow cytometry validated the engraftment of hCD45+ cells 14 days post implantation in each group of mice (n = 3/group). H Collagen content was assessed using Masson’s trichrome staining, while expression levels of α-SMA and CD8 were evaluated through mIHC analysis. Ki-67 and TUNEL staining were performed on PDX tumor tissues to assess cell apoptosis and proliferation. H&E analysis was conducted on tumor tissues from each group. I, J Collagen content assessed by Masson’s trichrome staining, and expression levels of α-SMA evaluated by IHC analysis. IOD: Integrated Optical Density. K TUNEL staining was performed to evaluate cell apoptosis. All results are presented as mean ± SEM. P values were determined by one-way ANOVA. **P < 0.01, ***P < 0.001.

  • Open Access

    Table S3 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

    Plasma SPP1-stratified demographic features of 156 GC patients treated with ICBs.

  • Open Access

    Figure S8 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

    Figure S8 High plasma SPP1 levels are associated with poor response to immunotherapy in GC patients. A, B Statistical analysis of irOS (A) and irPFS (B) in the SPP1 lower and SPP1 higher groups. C-F Statistical analysis of the best treatment efficacy results in the SPP1 lower and SPP1 higher groups. Data in scatter plots indicate mean ± SEM. ***P < 0.001. Log-rank test (A, B), Student’s t test (C-E), one-way ANOVA (F). CR, Complete Response; PR, Partial Response; PD, Progressive Disease; SD, Stable Disease; irOS, immune-related Overall Survival; irPFS, immune-related Progression-Free Survival; ORR, Objective Response Rate; DCR, Disease Control Rate.

  • Open Access

    Table S2 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

  • Open Access

    Table S1 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

  • Open Access

    Figure S5 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

    Figure S5 SPP1-CD44 interaction activates β-catenin/HIF-1α signaling in CAFs. A GSEA analysis of RNA-seq data from CAFs derived from primary tumors (PT-CAFs) and liver metastases (LM-CAFs) of CRC patients. B qRT-PCR and western blot assessed the knockdown efficiency of si-CTNNB1 in CAFs. C qRT-PCR was used to evaluate the mRNA expression of HIF1A in CAFs with CTNNB1 knockdown (left) or MSAB treatment (right), n = 3 biologically independent experiments. D Western blot analysis was performed to assess the protein expression of HIF-1α in CAFs with CTNNB1 knockdown or MSAB treatment. E qRT-PCR and western blot assessed the knockdown efficiency of si-HIF1A in CAFs. F qRT-PCR was used to measure CD44 mRNA levels in T cells and different kind of CAFs. NAF: normal-associated fibroblasts; PT: primary tumor; LM: liver metastasis, n = 3 biologically independent experiments. G qRT-PCR and western blot assessed the knockdown efficiency of si-CD44 in CAFs. H, I Western blot analysis was conducted to evaluate HIF-1α and β-catenin protein expression in control (si-NC) and CD44 knockdown CAFs, with or without conditional medium from HCT116-HM (H) or LOVO-HM (I). J CAF cells were transfected with si-NC or si-CD44 and subsequently treated with conditioned medium from SPP1-overexpressing HCT116 or LoVo cells. The expression levels of β-catenin and HIF-1α were then assessed by western blot. K Western blot analysis was conducted to evaluate HIF-1α and β-catenin protein expression in control (si-NC) and CD44 knockdown CAFs, with or without rhSPP1 protein (1 µg/mL) treatment. L Nuclear-cytoplasmic fractionation was performed to assess the nuclear translocation of HIF-1α in control (si-NC) and CD44 knockdown CAFs, with or without treatment with rhSPP1 protein (1 µg/mL). Western blot experiments in (A, C, F-J) were repeated three times, the data are representative of three biologically independent experiments. All results are presented as mean ± SEM. P values were determined by two-tailed unpaired Student’s t test (C) and one-way ANOVA (B, E-G). ns, no significant difference, **P < 0.01, ***P < 0.001.

  • Open Access

    Figure S3 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

    Figure S3 SPP1 positively correlates with CAF marker expression and promotes FAP expression. A Correlation analysis of SPP1 with CAF marker genes from TCGA data. B Brightfield and fluorescence images of PT-PDOs #1 and LM-PDO #1 stably expressing GFP-SPP1. Green fluorescence indicates SPP1 expression. Scale bar, 500 μm. C Supernatants from PDOs overexpressing SPP1 or Vector were collected at various time points to stimulate CAFs, followed by western blot analysis of FAP level, n = 3 biologically independent experiments. CM, Conditional Medium.

  • Open Access

    Figure S4 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

    Figure S4 CAF enhances SPP1-induced suppression of T-cell cytotoxicity. A Schematic representation of the tumor cell and T cell coculture system with or without CAFs. B, C After 24 hours of coculture with or without CAFs, propidium iodide staining was used to identify LoVo (B) or HCT116 (C) cells killed by T cells. Fluorescence microscopy assessed the effects of SPP1 overexpression on T-cell cytotoxicity, n = 3 biologically independent experiments. Scale bar, 100 μm. D Schematic representation of the tumor cell and T cell coculture system, with or without CAFs and SPP1 protein (1 µg/mL) treatment. E, F After 24 hours of coculture with or without CAFs, propidium iodide staining was used to identify LoVo (E) or HCT116 (F) cells killed by T cells. Fluorescence microscopy assessed the effects of SPP1 protein (1 µg/mL) treatment on T-cell cytotoxicity, n = 3 biologically independent experiments. Scale bar, 100 μm. G Schematic representation of the tumor cell and T cell coculture system, with or without CXCL12 protein (100 ng/mL) or CXCL12-neutralizing antibody (100 ng/mL) treatment. H, I After 24 hours of coculture, propidium iodide labeling identified LoVo and HCT116 cells killed by T cells. Fluorescence microscopy assessed the effects of CXCL12 protein (100 ng/mL) or CXCL12-neutralizing antibody (100 ng/mL) treatment on T-cell cytotoxicity, n = 3 biologically independent experiments. Scale bar, 100 μm. All results are presented as mean ± SEM. P values were determined by one-way ANOVA. ns, no significant difference, *P < 0.05, ***P < 0.001. PI, propidium iodide.

  • Open Access

    Figure S7 from SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    by Shengde Liu, Zizhen Zhang, Zhenghang Wang, Cheng Liu, Guanghao Liang, Ting Xu, Zhiwei Li, Xiaorui Duan, Gehan Xu, Xujiao Feng, et al.

    Figure S7 Tumor-derived SPP1 promotes the progression of CRLM and immunotherapy resistance independent of macrophages. A Flowchart of the intrasplenic injection model of liver metastasis in mice using OE-SPP1 or OE-vector MC38 cells. i.s.v., intrasplenic injection; i.p., intraperitoneal injection. Clo: Clodronate-liposomes. B Representative H&E staining of metastatic livers from C57BL/6J mice intrasplenically implanted with SPP1-overexpressing or vector-overexpressing MC38 cells, followed by treatment with anti-PD-1 antibody. Scale bar, 1 mm. C Quantification of liver weight and tumor burden in liver metastases from the indicated mouse groups (n = 5 per group), with tumor burden assessed by the tumor-to-liver area ratio in tissue sections. D Flow cytometric analysis of macrophage populations in liver metastases from the indicated mouse groups (n = 5 per group). Mac+ represents the control group, MacΔ represents the macrophage depletion group. E, F Flow cytometric analysis of IFN-γ+ CD8+ and GZMB+ CD8+ T cell populations in liver metastases from the indicated mouse groups (n = 5 per group). G, H Collagen content was evaluated by Masson’s trichrome staining, α-SMA expression levels were assessed via IHC analysis, and cell apoptosis was measured by TUNEL staining. Integrated Optical Density (IOD) was used for quantification in all assays (n = 5 per group). Scale bar = 40 μm. I Flow cytometry validated the engraftment of hCD45+ cell 7 days post implantation in each group of mice (n = 3/group). All results are presented as mean ± SEM. P values were determined by one-way ANOVA. ns, no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.